A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer.
An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.
Understanding how a bacterial protein that influences the risk of stomach cancer is produced could guide new strategies for treatment.
For much of her career, Angelika Amon, PhD, recipient of the 2018 Vanderbilt Prize in Biomedical Science, has pursued a mystery with life-or-death consequences.
A Vanderbilt initiative to develop predictive imaging technologies that clinicians can use to better match patients with personalized care has received National Cancer Institute (NCI) funding.
Around two-thirds of patients treated for breast cancer will have had hormone-sensitive tumors and, after their initial treatment, will be advised to undergo hormone therapy for five to 10 years to prevent recurrence.
Accessibility Tools